Drug Search Results
Using advanced filters...
Advanced Search [+]

Esflurbiprofen

Alternative Names: esflurbiprofen
Latest Update: 2025-04-04
Latest Update Note: Clinical Trial Update

Product Description

Esflurbiprofen is a topically applied, non-steroidal anti inflammatory drug (NSAID). It is the more active enantiomer of racemic flurbiprofen. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9420)

Mechanisms of Action: COX Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Transdermal,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan | Malaysia | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Teikoku
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Esflurbiprofen

Countries in Clinic: Germany

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Acute Pain|Ankle Injuries|Contusions

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TK-254RX-0302

P3

Recruiting

Contusions

2025-11-01

TK-254RX-0301

P3

Unknown Status

Acute Pain

2025-08-31

TK-254RX-0302

P3

Unknown Status

Contusions

2025-08-31

TK-254RX-0301

P3

Recruiting

Ankle Injuries

2025-08-01

Recent News Events

Date

Type

Title